Summary box
What is already known on this topic?COVID-19 mRNA vaccine efficacy wanes over time in vaccinated adults; a third vaccine booster is now recommended for individuals over 16 years of age six-months after the two-vaccine series is completed.
What is added by this report?We tested antibody durability of vaccine-induced full SARS-CoV-2 Spike and receptor binding domain (RBD) antibodies, as well as antibody levels specifically targeting the predominant variant of concern, Omicron, in younger adolescent children.
What are the implications for public health practice?Waning anti-SARS-CoV-2 antibodies in adolescents support urgent authorization for a COVID-19 mRNA booster in the 12-15-year-old age group.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Massachusetts General Hospital for Children, Nancy Zimmerman, Mark and Lisa Schwartz, an anonymous donor (financial support), Terry and Susan Ragon, and the SAMANA Kay MGH Research Scholars award, (MassCPR), the NIH, the Gates Foundation Global Health Vaccine Accelerator Platform funding (OPP1146996 and INV-001650), and the Musk Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
MGB IRB #2020P000955
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
